Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2014

Open Access 01-12-2014 | Research

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Authors: Sven de Vos, Andres Forero-Torres, Stephen M Ansell, Brad Kahl, Bruce D Cheson, Nancy L Bartlett, Richard R Furman, Jane N Winter, Henry Kaplan, John Timmerman, Nancy C Whiting, Jonathan G Drachman, Ranjana Advani

Published in: Journal of Hematology & Oncology | Issue 1/2014

Login to get access
Metadata
Title
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Authors
Sven de Vos
Andres Forero-Torres
Stephen M Ansell
Brad Kahl
Bruce D Cheson
Nancy L Bartlett
Richard R Furman
Jane N Winter
Henry Kaplan
John Timmerman
Nancy C Whiting
Jonathan G Drachman
Ranjana Advani
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2014
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-7-44

Other articles of this Issue 1/2014

Journal of Hematology & Oncology 1/2014 Go to the issue

Review

Nucleo-cytoplasmic transport as a therapeutic target of cancer

Editorial

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents

Review

Toll-like receptors in the pathogenesis of human B cell malignancies

Review

Signaling pathways in the development of infantile hemangioma

Research

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma

Review

T cell immune abnormalities in immune thrombocytopenia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits